Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 1/20 | 0.59 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.59 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.58 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.56 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.56 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.56 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.56 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288721 | 0.83 | CYP3A4 (0.59) | QPCTQPCTLTBXAS1HRH4ALDH1A1 | |
| SCHEMBL9906891 | 0.83 | QPCT (0.59) | QPCTQPCTLHRH4ALDH1A1CYP3A4 | |
| SCHEMBL1527998 | 0.80 | TBXAS1 (0.72) | QPCTQPCTLTBXAS1HRH4ALDH1A1 | |
| SCHEMBL18381205 | 0.80 | CYP3A4 (0.74) | QPCTQPCTLTBXAS1ALDH1A1CYP3A4 | |
| SCHEMBL2755863 | 0.79 | QPCT (0.73) | QPCTQPCTLHRH4ALDH1A1CYP3A4 | |
| Hydrochloric Acid SCHEMBL1371691 | 0.79 | TBXAS1 (0.75) | QPCTQPCTLTBXAS1HRH4ALDH1A1 | |
| SCHEMBL21858082 | 0.77 | QPCT (0.75) | QPCTQPCTLHRH4ALDH1A1CYP3A4 | |
| SCHEMBL13851684 | 0.77 | TBXAS1 (0.84) | TBXAS1HRH4ALDH1A1CYP3A4TSHR | |
| SCHEMBL17483161 | 0.77 | QPCT (0.75) | QPCTQPCTLHRH4ALDH1A1CYP3A4 | |
| SCHEMBL18381218 | 0.77 | CYP3A4 (0.70) | QPCTQPCTLTBXAS1HRH4CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170216-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20230295259-A1 | Conjugated Hepcidin Mimetics | PROTAGONIST THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| CN-104284891-B | Conformationally constrained, fully synthetic macrocyclic compounds | 波利弗尔股份公司 | 2018-04-17 | — | — | CN | disclosed |
| EP-2427476-A1 | BETA-HAIRPIN PEPTIDOMIMETICS HAVING CXCR4 ANTAGONIZING ACTIVITY | Polyphor Ag (CH) | 2012-03-14 | — | — | EP | disclosed |
| WO-2011066869-A1 | BETA-HAIRPIN PEPTIDOMIMETICS | POLYPHOR AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| WO-2010127704-A1 | BETA-HAIRPIN PEPTIDOMIMETICS HAVING CXCR4 ANTAGONIZING ACTIVITY | POLYPHOR AG (CH) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295259-A1 | Conjugated Hepcidin Mimetics | HAMP, VIP, HDGF | QPCT 162/4885QPCTL 155/4885TBXAS1 1570/4885 |
| US-20250170216-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | QPCT 259/4885QPCTL 260/4885TBXAS1 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.